摘要
目的探讨麝香保心丸预防糖尿病患者冠脉支架术后再狭窄的临床效果。方法选取我院2018年6~12月收治的100例糖尿病且行PCI术的冠心病患者作为研究对象,按照"电脑随机法"将患者分为观察组和对照组,每组50例,其中对照组给予常规方式进行治疗,观察组在对照组基础上应用麝香保心丸治疗;治疗后比较两组患者冠脉支架术后再狭窄发生率、血小板活化标志物和血管内皮功能指标、血脂和血清hs-CRP、TNF-α水平。结果观察组糖尿病患者冠脉支架术后再狭窄发生率(2.00%)低于对照组,差异有统计学意义(P<0.05);观察组糖尿病患者CD62P(4.66±1.32)%、CD63P(2.61±0.21)%、GPⅡb/Ⅲa受体复合物(9.66±1.34)%、vWF(89.54±1.54)%、ET-1(55.25±1.64)ng/L,均低于对照组,NO(78.81±1.20)μmol/L高于对照组,差异有统计学意义(P<0.05)。观察组糖尿病患者TC(3.22±0.31)mmol/L、HDL-C(1.01±0.03)mmol/L、LDL-C(2.66±0.14)mmol/L、TG(1.31±0.22)mmol/L、hs-CRP(3.26±1.08)mg/L、TNF-α(0.22±0.04)μg/L均低于对照组,差异有统计学意义(P<0.05)。结论麝香保心丸能够明显降低冠脉支架术后再狭窄发生率、血脂和炎性因子水平,值得在临床中推广应用。
Objective To study the clinical effect of Shexiang Baoxin Pill in preventing restenosis after coronary stenting in diabetic patients. Methods 100 patients with coronary heart disease who underwent PCI in our hospital from June to December 2018 were enrolled. The patients were divided into observation group and control group according to the "computer randomization method", with 50 cases in each group. The control group was treated with conventional methods, and the observation group was treated with Shexiang Baoxin Pill on the basis of the treatment of the control group. After treatment, the incidence of restenosis after coronary stenting, platelet activation markers, vascular endothelial function, blood lipids and serum hs-CRP, TNF-α levels were compared between the two groups. Results The incidence of restenosis after coronary stenting in the observation group was 2.00%, lower than that in the control group (P<0.05). The CD62P (4.66±1.32)%, CD63P (2.61±0.21)%, GPIIb/IIIa receptor complex (9.66±1.34)%, vWF (89.54±1.54)%, ET-1(55.25±1.64) ng/L in the observation group were lower than those of the control group, and the NO (78.81±1.20)μmol/L in the observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). The TC (3.22±0.31) mmol/L, HDL-C (1.01±0.03) mmol/L, LDL-C (2.66±0.14) mmol/L, TG (1.31±0.22) mmol/L, hs-CRP (3.26±1.08) mg/L and TNF-α(0.22±0.04)μg/L in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Shexiang Baoxin Pill can significantly reduce the incidence of restenosis after coronary stenting, blood lipids and inflammatory factors, and it is worthy of popularization in clinical practice.
作者
张伟
梅益斌
喻晖
ZHANG Wei;MEI Yibin;YU Hui(Department of Cardiology,Lishui People's Hospital in Zhejiang Province,Lishui 323000,China)
出处
《中国现代医生》
2019年第26期115-118,共4页
China Modern Doctor
基金
浙江省中医药科技计划项目(2016ZB144)
关键词
麝香保心丸
预防
糖尿病
冠脉支架术后再狭窄
Shexiang Baoxin Pill
Prevention
Diabetes
Restenosis after coronary stenting
